{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:00:04Z","timestamp":1774598404834,"version":"3.50.1"},"reference-count":23,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Data evaluating the use of unlicensed cannabidiol (CBD) products for the treatment of \u00adsymptoms associated with anxiety and neurodevelopmental disorders in children are limited despite increasing \u00adproduct availability. The objectives of this study are to quantify the usage of unlicensed CBD products among pediatric patients diagnosed with anxiety and neurodevelopmental disorders and compare the \u00adperceptions of CBD between parents who administer a CBD product to a child and parents who do not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A survey containing 31 items was designed after pretesting with pediatric health care professionals. The refined survey was distributed using Qualtrics Panels to a representative sample of US parents of a child 7 to 18 years of age diagnosed with attention-deficit\/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and\/or generalized anxiety disorder (GAD). Responses were analyzed with descriptive \u00adstatistics and compared using a \u03c72 or Mann-Whitney U test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of the 518 completed surveys, 162 parents (31.3%) reported the administration of an unlicensed CBD product to a child with ADHD, ASD, and\/or GAD. The highest prevalence of use was found in the West geographic region and among children diagnosed with GAD or with 2 or more diagnoses (i.e., ADHD, ASD, GAD). Parents who administered CBD products had more positive views of product safety and higher \u00adperceived community support for usage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Nearly one-third of parents have administered an unlicensed CBD product to a child with ADHD, ASD, and GAD. Health care providers should assess pediatric patients for CBD use and be prepared to engage parents in conversations regarding the safety of these products.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-28.4.323","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T12:30:34Z","timestamp":1691843434000},"page":"323-328","source":"Crossref","is-referenced-by-count":1,"title":["Parental Perceptions and Usage of Unlicensed Cannabidiol Products in Children With Anxiety and Neurodevelopmental Disorders"],"prefix":"10.5863","volume":"28","author":[{"given":"Kathryn","family":"Schwaller","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Cedarville University School of Pharmacy, Cedarville, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Krauss","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Cedarville University School of Pharmacy, Cedarville, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleda M.H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Cedarville University School of Pharmacy, Cedarville, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin W.","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Cedarville University School of Pharmacy, Cedarville, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"2023081212302415200_i2331-348X-28-4-323-b1","article-title":"FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD)","author":"US Food and Drug Administration"},{"key":"2023081212302415200_i2331-348X-28-4-323-b2","article-title":"FDA and cannabis: research and drug approval process","author":"US Food and Drug Administration"},{"issue":"1","key":"2023081212302415200_i2331-348X-28-4-323-b3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MOP.0000000000000861","article-title":"The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children","volume":"32","author":"Singer","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"2023081212302415200_i2331-348X-28-4-323-b4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2018","journal-title":"Front Pharmacol"},{"issue":"9","key":"2023081212302415200_i2331-348X-28-4-323-b5","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: hope or hype?","volume":"239","author":"Pedrazzi","year":"2022","journal-title":"Psychopharmacology"},{"issue":"8","key":"2023081212302415200_i2331-348X-28-4-323-b6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023081212302415200_i2331-348X-28-4-323-b7","first-page":"e20200149","article-title":"Cannabis and cannabinoid use in autism spectrum disorder: a systematic review","volume":"44","author":"Silva Junior","year":"2022","journal-title":"Trends Psychiatry Psychother"},{"issue":"5","key":"2023081212302415200_i2331-348X-28-4-323-b8","doi-asserted-by":"crossref","first-page":"21m14130","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial","volume":"83","author":"Berger","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"2023081212302415200_i2331-348X-28-4-323-b9","author":"Global Market Insights. Cannabidiol market size"},{"key":"2023081212302415200_i2331-348X-28-4-323-b10","author":"US Census Bureau. Geographic levels"},{"issue":"6","key":"2023081212302415200_i2331-348X-28-4-323-b11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1542\/peds.2008-2173","article-title":"The use of complementary and alternative medicine in pediatrics","volume":"122","author":"Kemper","year":"2008","journal-title":"Pediatr"},{"key":"2023081212302415200_i2331-348X-28-4-323-b12","doi-asserted-by":"crossref","first-page":"102527","DOI":"10.1016\/j.ctim.2020.102527","article-title":"Complementary and alternative medicine use in children with a developmental disability and co-occurring medical conditions","volume":"53","author":"Zisman","year":"2020","journal-title":"Complement Ther Med"},{"key":"2023081212302415200_i2331-348X-28-4-323-b13","author":"World Population Review. CBD legal states in 2022"},{"issue":"17","key":"2023081212302415200_i2331-348X-28-4-323-b14","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2023081212302415200_i2331-348X-28-4-323-b15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s42238-022-00140-1","article-title":"Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim","volume":"4","author":"Johnson","year":"2022","journal-title":"J Cannabis Res"},{"key":"2023081212302415200_i2331-348X-28-4-323-b16","article-title":"CBD market report: over half of CBD products are mislabeled","author":"Leafreport"},{"key":"2023081212302415200_i2331-348X-28-4-323-b17","article-title":"Cannabidiol (CBD)","author":"America\u2019s Poison Control Centers"},{"key":"2023081212302415200_i2331-348X-28-4-323-b18","article-title":"What you need to know (and what we\u2019re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD","author":"US Food and Drug Administration"},{"key":"2023081212302415200_i2331-348X-28-4-323-b19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.socscimed.2017.08.003","article-title":"Parent use of cannabis for intractable pediatric epilepsy: everyday empiricism and the boundaries of scientific medicine","volume":"190","author":"Sobo","year":"2017","journal-title":"Soc Sci Med"},{"issue":"2","key":"2023081212302415200_i2331-348X-28-4-323-b20","doi-asserted-by":"crossref","first-page":"E563","DOI":"10.9778\/cmajo.20200212","article-title":"Family attitudes about and experiences with medical cannabis in children with cancer or epilepsy: an exploratory qualitative study","volume":"9","author":"Gibbard","year":"2021","journal-title":"CMAJ Open"},{"issue":"1","key":"2023081212302415200_i2331-348X-28-4-323-b21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09638288.2017.1370497","article-title":"(Unpacking) father involvement in the context of childhood neurodisability research: a scoping review","volume":"41","author":"Bogossian","year":"2019","journal-title":"Disabil Rehabil"},{"issue":"3","key":"2023081212302415200_i2331-348X-28-4-323-b22","doi-asserted-by":"crossref","first-page":"e20171961","DOI":"10.1542\/peds.2017-1961","article-title":"Pediatric integrative medicine","volume":"140","author":"McClafferty","year":"2017","journal-title":"Pediatrics"},{"key":"2023081212302415200_i2331-348X-28-4-323-b23","doi-asserted-by":"crossref","first-page":"2333794X18815412","DOI":"10.1177\/2333794X18815412","article-title":"Autism spectrum disorder and cannabidiol: Have we seen this movie before?","volume":"5","author":"Salgado","year":"2018","journal-title":"Global Pediatr Health"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/4\/323\/3248430\/i2331-348x-28-4-323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/4\/323\/3248430\/i2331-348x-28-4-323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:38:30Z","timestamp":1738780710000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/4\/article-p323.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,9]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.4.323","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}